Chujie Bai1, Xiuli Ma2, Xinyu Wang1, Xiaoya Chen3. 1. Department of Bone and Soft Tissue Tumor, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute Beijing 100142, China. 2. Department of Pathology, Peking University Cancer Hospital Beijing 100142, China. 3. School of Biomedical Engineering and Technology, Tianjin Medical University Tianjin 300203, China.
Abstract
OBJECTIVE: To analyze the pathological features of patients with osteosarcoma and the correlation of expressions of transferrin receptor 1 (TfR1), vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP)-9 in tumor tissue with the pathological features. METHODS: The tumor tissue and paracancerous tissue samples from 31 patients with osteosarcoma were collected before treatment to measure the expressions of TfR1, VEGF and MMP-9. Kaplan-meier curve was used to analyze the relationship of TfR1, VEGF and MMP-9 with the survival time of patients. Log-rank test was used to test the difference, and Spearman test was used to test the correlation. RESULTS: Among the 31 osteosarcoma samples, 23 (74.19%), 24 (77.42%) and 17 (54.84%) samples showed medium-high expressions of VEGF, TfR1 and MMP-9, respectively, which were significantly higher than those in the paracancerous samples (P<0.05). Furthemore, the medium-high expression rates of VEGF, TfR1 and MMP-9 were significantly different in patients with different Enneking stages, different histological differentiation degrees, and with or without distant metastasis. Besides, the expression of VEGF was also significantly different in different-size osteosarcoma samples (P<0.05). The survival time of patients with low expressions of TfR1, VEGF and MMP-9 was significantly longer than that of patients with medium-high expressions (P<0.05). Additionally, in osteosarcoma samples, significant positive correlations were shown between the expressions of TfR1 and VEGF, as well as between TfR1 and MMP-9 (P<0.05), but there was no significant correlation between VEGF and MMP-9 (P>0.05). CONCLUSION: TfR1, VEGF and MMP-9 are abnormally expressed in osteosarcoma lesions, suggesting that they all play a role in the occurrence and development of osteosarcoma. AJTR
OBJECTIVE: To analyze the pathological features of patients with osteosarcoma and the correlation of expressions of transferrin receptor 1 (TfR1), vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP)-9 in tumor tissue with the pathological features. METHODS: The tumor tissue and paracancerous tissue samples from 31 patients with osteosarcoma were collected before treatment to measure the expressions of TfR1, VEGF and MMP-9. Kaplan-meier curve was used to analyze the relationship of TfR1, VEGF and MMP-9 with the survival time of patients. Log-rank test was used to test the difference, and Spearman test was used to test the correlation. RESULTS: Among the 31 osteosarcoma samples, 23 (74.19%), 24 (77.42%) and 17 (54.84%) samples showed medium-high expressions of VEGF, TfR1 and MMP-9, respectively, which were significantly higher than those in the paracancerous samples (P<0.05). Furthemore, the medium-high expression rates of VEGF, TfR1 and MMP-9 were significantly different in patients with different Enneking stages, different histological differentiation degrees, and with or without distant metastasis. Besides, the expression of VEGF was also significantly different in different-size osteosarcoma samples (P<0.05). The survival time of patients with low expressions of TfR1, VEGF and MMP-9 was significantly longer than that of patients with medium-high expressions (P<0.05). Additionally, in osteosarcoma samples, significant positive correlations were shown between the expressions of TfR1 and VEGF, as well as between TfR1 and MMP-9 (P<0.05), but there was no significant correlation between VEGF and MMP-9 (P>0.05). CONCLUSION: TfR1, VEGF and MMP-9 are abnormally expressed in osteosarcoma lesions, suggesting that they all play a role in the occurrence and development of osteosarcoma. AJTR
Authors: Neyssa M Marina; Sigbjørn Smeland; Stefan S Bielack; Mark Bernstein; Gordana Jovic; Mark D Krailo; Jane M Hook; Carola Arndt; Henk van den Berg; Bernadette Brennan; Bénédicte Brichard; Ken L B Brown; Trude Butterfass-Bahloul; Gabriele Calaminus; Heike E Daldrup-Link; Mikael Eriksson; Mark C Gebhardt; Hans Gelderblom; Joachim Gerss; Robert Goldsby; Allen Goorin; Richard Gorlick; Holcombe E Grier; Juliet P Hale; Kirsten Sundby Hall; Jendrik Hardes; Douglas S Hawkins; Knut Helmke; Pancras C W Hogendoorn; Michael S Isakoff; Katherine A Janeway; Heribert Jürgens; Leo Kager; Thomas Kühne; Ching C Lau; Patrick J Leavey; Stephen L Lessnick; Leo Mascarenhas; Paul A Meyers; Hubert Mottl; Michaela Nathrath; Zsuzsanna Papai; R Lor Randall; Peter Reichardt; Marleen Renard; Akmal Ahmed Safwat; Cindy L Schwartz; Michael C G Stevens; Sandra J Strauss; Lisa Teot; Mathias Werner; Matthew R Sydes; Jeremy S Whelan Journal: Lancet Oncol Date: 2016-08-25 Impact factor: 41.316